Efficacy and safety of procalcitonin guidance in reducing the duration of antibiotic treatment in critically ill patients: a randomised, controlled, open-label trial.
By E. D. de Jong, J. V. van Oers, A. Beishuizen, P. Vos, Wytze J. Vermeijden, L. Haas, B. Loef, T. Dormans, G. C. van Melsen, Yvette Kluiters and 20 more. Lancet. Infectious Diseases (Print), 2016
717 citations recorded by the source corpus.
Subfields: Applied Microbiology and Biotechnology, Critical Care and Intensive Care Medicine, Epidemiology
View Paper: https://www.semanticscholar.org/paper/88f46075196e9fcaaca17ce863d6f59a003c9d90
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
In Critical Care and Intensive Care Medicine
In Epidemiology
- A. Rhodes
- Laura Evans
- Janice L. Zimmerman
- Mitchell M. Levy
- R. Dellinger
- Mervyn Singer
- Djillali Annane
Citations in the corpus
- Bacterial and fungal co-infection in individuals with coronavirus: A rapid review to support COVID-19 antimicrobial prescribing (2020, background): “Procalcitonin has been demonstrated to support differentiation between bacterial and viral infection and supports early cessation of antibiotics in confirmed bacterial infection with no effect on patient mortality [41, 42].”
- Surviving Sepsis Campaign: International Guidelines for Management of Sepsis and Septic Shock: 2016 (2017, background): “Recently, a large randomized trial on procalcitonin use in critically ill patients with presumed bacterial infection demonstrated evidence of a reduction in duration of treatment and daily defined doses of antimicrobials (217).”
- Surviving Sepsis Campaign International Guidelines for the Management of Septic Shock and Sepsis-Associated Organ Dysfunction in Children (2020, background): “In adults with severe infections and sepsis, procalcitonin has been shown to successfully guide de-escalation (126–130) with an associated improved mortality (131).”